Levosimendan Bioglan

Levosimendan, the active ingredient in Levosimendan Bioglan, is a calcium sensitizer presented as an injection for intravenous use. It is employed in the management of acute decompensated heart failure to improve cardiac contractility and reduce symptoms in hospitalized patients.

GNH USA supplies Levosimendan Bioglan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product conforms to EU market standards and is manufactured under GMP conditions.

Levosimendan is indicated for conditions affecting cardiac contractility and systemic circulation.

- Acute decompensated heart failure: improves cardiac output and alleviates symptoms in patients with sudden worsening of heart failure. - Cardiogenic shock: provides inotropic support to stabilize hemodynamics when conventional therapies are insufficient. - Post‑cardiac surgery low cardiac output syndrome: enhances myocardial performance to facilitate recovery after cardiac operations.

Levosimendan may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Hypotension: transient drop in blood pressure. - Tachycardia: increased heart rate. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked blood pressure decline requiring intervention. - Myocardial ischemia: reduced blood flow to heart muscle. - Pulmonary edema: fluid accumulation in lungs. - Anaphylactic reaction: rare hypersensitivity requiring emergency care.

When using Levosimendan, clinicians should observe specific precautions to minimize risk.

- Cardiac monitoring: continuous ECG and hemodynamic assessment during infusion. - Blood pressure: monitor for hypotension, especially in patients on vasodilators. - Electrolytes: correct potassium and magnesium abnormalities before administration. - Renal impairment: adjust use in severe renal dysfunction due to altered drug clearance. - Hepatic dysfunction: use cautiously in patients with significant liver disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Nitrates: additive vasodilatory effect can cause severe hypotension. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive response. - Beta‑blockers: may blunt desired inotropic effect. - Calcium channel blockers: possible additive cardiovascular effects.